Core Insights - STERIS plc reported a strong financial performance for the first quarter of fiscal 2026, with total revenue from continuing operations increasing by 9% to $1.4 billion compared to $1.3 billion in the same period last year [1][8] - The company experienced an adjusted net income of $231.2 million or $2.34 per diluted share, up from $201.7 million or $2.03 per diluted share in the previous year [2][8] Financial Performance - Total revenue from continuing operations increased by 9% to $1.4 billion, with constant currency organic revenue growth at 8% [1][9] - Net income from continuing operations was $177.4 million or $1.79 per diluted share, compared to $139.8 million or $1.41 per diluted share in the first quarter of fiscal 2025 [2][8] - Free cash flow for the first quarter was $326.5 million, an increase from $195.7 million in the prior year [6][10] Segment Performance - Healthcare revenue grew by 8% to $974.7 million, driven by a 13% increase in service revenue, 6% in capital equipment revenue, and 5% in consumable revenue [3][8] - Applied Sterilization Technologies (AST) revenue increased by 13% to $281.2 million, with a 46% rise in capital equipment revenue [4][8] - Life Sciences revenue rose by 5% to $135.2 million, supported by an 8% increase in consumable revenue [5][8] Outlook - The company updated its fiscal 2026 revenue outlook, now expecting an increase of 8-9% compared to previous expectations of 6-7% [9][10] - Adjusted earnings per diluted share are expected to remain in the range of $9.90 to $10.15, despite increased tariffs and higher employee healthcare costs [9][10] - Free cash flow is now anticipated to be approximately $820 million, up from prior expectations of $770 million [10] Board Changes - STERIS announced changes to its Board, with Dr. Jaqueline Kosecoff and Dr. Richard Steeves retiring, and Louis Shapiro being elected to the Board [7][9]

Core Insights - STERIS plc (STE) is set to announce its first-quarter fiscal 2026 results on August 7, with previous quarter adjusted EPS of $2.74, exceeding Zacks Consensus Estimate by 5.79% [1] - The Zacks Consensus Estimate for revenues is $1.36 billion, reflecting a 6.2% increase year-over-year, while EPS is estimated at $2.32, indicating a 14.3% year-over-year growth [2] Revenue Estimates - Healthcare segment is expected to show robust growth driven by increased procedure volumes in the U.S. and gains in pricing and market share [4] - Healthcare capital equipment order growth is anticipated to remain strong despite shipment issues, with projected revenue growth of 5.1% year-over-year [5] - Applied Sterilization Technologies (AST) segment is expected to see organic revenue growth, with revenues likely increasing by 6.3% year-over-year [6][7] Life Sciences Segment - Life Sciences segment revenues may rise by 5.5% year-over-year, supported by favorable mix, pricing, and divestiture, despite a decline in capital equipment revenue [8][9] Earnings Expectations - STERIS has an Earnings ESP of -3.24%, indicating a lower likelihood of beating earnings estimates this quarter [10] - The company currently holds a Zacks Rank of 3, suggesting a hold position [10]

Core Points - STERIS plc announced a quarterly interim dividend of $0.63 per share, marking a $0.06 increase and the 20th consecutive year of dividend growth [1] - The dividend is scheduled to be paid on September 26, 2025, to shareholders of record as of September 4, 2025 [1] Company Overview - STERIS is a leading global provider of products and services that support patient care, with a focus on infection prevention [2] - The company aims to help customers create a healthier and safer world through innovative healthcare and life science products and services [2]

Group 1 - Steris is expected to report a year-over-year increase in earnings, with a consensus estimate of $2.32 per share, reflecting a +14.3% change, and revenues projected at $1.36 billion, up 6.2% from the previous year [3][12] - The earnings report is anticipated to be released on August 6, and the actual results will significantly influence the stock price, depending on whether they meet or exceed expectations [2][12] - The consensus EPS estimate has been revised 0.1% higher in the last 30 days, indicating a slight positive adjustment by analysts [4] Group 2 - The Earnings ESP for Steris is -3.24%, suggesting a bearish outlook from analysts, which complicates the prediction of an earnings beat [12] - Historically, Steris has beaten consensus EPS estimates three out of the last four quarters, with a recent surprise of +5.79% in the last reported quarter [13][14] - The Zacks Rank for Steris is currently 3 (Hold), which, combined with the negative Earnings ESP, makes it challenging to predict a positive earnings surprise [12][19] Group 3 - In the broader industry context, CVRx is expected to report a loss of $0.52 per share, indicating a +20% year-over-year change, with revenues projected at $13.46 million, up 14% [18] - CVRx's consensus EPS estimate has remained unchanged over the last 30 days, but it has an Earnings ESP of -0.65%, reflecting a lower Most Accurate Estimate [19]

Core Viewpoint - STERIS plc will host a conference call to discuss its fiscal 2026 first quarter results on August 7, 2025, with a press release detailing financial results to be issued after the U.S. market closes on August 6, 2025 [1][2]. Company Information - STERIS is a leading global provider of products and services that support patient care, focusing on infection prevention and aiming to create a healthier and safer world through innovative healthcare and life science products and services [3]. Conference Call Details - The conference call will take place at 9:00 a.m. ET on August 7, 2025, and can be accessed live via the company's website or by phone [1]. - A replay of the conference call will be available starting at 12:00 p.m. ET on the same day, with specific access codes provided for both U.S. and international callers [2]. Contact Information - For inquiries, the company contact is Julie Winter, Vice President of Investor Relations and Corporate Communications, reachable via email or phone [4].

Core Viewpoint - Steris (STE) has experienced significant selling pressure, declining 6% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory, with analysts expecting better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - STE's current RSI reading is 27.46, suggesting that the heavy selling pressure may be exhausting itself, indicating a potential trend reversal [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for STE have increased by 0.1% over the last 30 days, which usually correlates with price appreciation in the near term [7]. - STE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

Core Insights - STERIS plc's Healthcare segment is benefiting from strong market adoption of its infection prevention products and capital equipment, while the Applied Sterilization Technologies (AST) division is seeing solid growth due to increased service revenues [1][4][5] - The company has shown resilience in its stock performance, with a 6.2% increase over the past year, contrasting with a 12.2% decline in the industry [2] - STERIS has a market capitalization of $22.88 billion and an earnings yield of 4.4%, outperforming the industry's -2.9% [2] Healthcare Segment Performance - The Healthcare segment reported a 5% year-over-year revenue growth for the fourth quarter of fiscal 2025, driven by a 6% increase in consumable revenues and a 13% growth in service revenues [4] - The segment achieved a 6% constant currency organic revenue growth for the fiscal fourth quarter, with order growth exceeding 12% [4][8] - Margins improved due to increased volume, favorable pricing, and positive productivity, which offset labor inflation [4] AST Segment Growth - The AST division experienced a 9% year-over-year growth in the fiscal fourth quarter, supported by a 6% increase in service revenues [5] - The division is gaining traction with ethylene oxide sterilization, particularly among manufacturers of single-use sterile technologies for vaccines and biopharmaceuticals [5] - Constant currency organic revenues in the AST segment were in the high single digits, indicating strong demand from bioprocessing and stable global demand from MedTech customers [5] Financial Health - As of the fiscal fourth quarter of 2025, STERIS reduced its long-term debt by 38.5% to $1.92 billion from $3.12 billion a year earlier [6][9] - The company ended the fiscal third quarter with cash and cash equivalents of $171.7 million, exceeding its short-term debt of $125 million [6] - The total debt-to-capital ratio was 22.5%, down 33.2% year over year, indicating improved solvency [9] Challenges Facing the Company - The global macroeconomic environment has negatively impacted STERIS' financial operations, with rising healthcare costs and procurement challenges affecting production costs [10] - Customer consolidation due to competitive pressures and cost reduction measures has led to pricing pressure and potential customer loss for STERIS [11] Earnings Estimates - The Zacks Consensus Estimate for STERIS' fiscal 2026 earnings has increased by 0.9% to $10.11, with revenues projected at $5.83 billion, suggesting a 6.7% growth from fiscal 2024 [12]

Investor Presentation June 2025 Forward Looking Statements This presentation contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward- looking statements speak only as to the date the statemen ...

Core Insights - The article discusses the evolution of U.S. tariff policies and their impact on the sterile container system industry, highlighting the urgency for Chinese companies to internationalize due to domestic market saturation and global opportunities [2][3]. Section Summaries 1. U.S. Tariff Policy Evolution and Impact on the Sterile Container System Industry - The article defines sterile container system products and analyzes the core aspects of U.S. tariff policies [2]. - It emphasizes the impact of U.S. tariff adjustments on global supply chains and the necessity for Chinese sterile container system companies to expand internationally [2][3]. - The research aims to analyze policy impacts and summarize corporate strategies while providing future planning recommendations [2]. 2. Industry Impact Assessment - The article outlines optimistic, conservative, and pessimistic scenarios for the global sterile container system industry scale trends from 2024 to 2031 [3][9]. - It discusses the direct effects of tariff policies on Chinese sterile container system companies, including cost pressures and market access challenges [3][4]. 3. Global Market Share of Enterprises - The article presents the market share and rankings of major global sterile container system companies based on revenue and sales from 2022 to 2025, with 2025 being a forecast year [3][11]. - It includes data on sales revenue, market share, and pricing trends for these companies [3][11]. 4. Corporate Response Strategies - The article suggests strategies for companies to shift from export dependence to global capacity layout, including regional production networks and localized technology strategies [4][5]. - It emphasizes the importance of optimizing supply chain resilience and diversifying markets, particularly in emerging markets [4][5]. 5. Future Outlook: Global Industry Restructuring and China's Role - The article provides long-term trend predictions and strategic recommendations for the sterile container system industry [4][5]. 6. Current Global Capacity Distribution - The article forecasts global sterile container system supply and demand from 2020 to 2031, detailing production capacity, output, and utilization rates [6][7]. 7. Market Size and Growth Potential in Key Regions - The article analyzes the sales volume and revenue of the global sterile container system market, comparing data from 2020, 2024, and 2031 [7][8]. 8. Overview of Major Global Manufacturers - The article includes profiles of major manufacturers in the sterile container system market, detailing their production bases, sales regions, and market positions [8][9]. 9. Product Type Scale Analysis - The article categorizes sterile container systems by product type, including plastic, glass, and metal containers, and compares sales revenue and volume forecasts [9][10]. 10. Application Scale Analysis - The article categorizes sterile container systems by application, including hospitals, clinics, and laboratories, and provides sales and revenue forecasts [10][11].

Company Overview - Steris shares have decreased by approximately 1.8% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Steris have trended downward in the past month, indicating a negative outlook [2][4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the upcoming months [4] VGM Scores - Steris has an average Growth Score of C, a Momentum Score of C, and a Value Score of C, placing it in the middle 20% for investment strategies [3] Industry Performance - Steris is part of the Zacks Medical - Instruments industry, where Pacific Biosciences of California (PACB) has seen a gain of 11.3% over the past month [5] - Pacific Biosciences reported revenues of $37.15 million for the last quarter, reflecting a year-over-year decline of 4.3% [5] - The expected loss for Pacific Biosciences in the current quarter is $0.18 per share, with a year-over-year improvement of 10% [6]